Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
Stimpfle F, Karathanos A, Droppa M, Metzger J, Rath D, Müller K, Tavlaki E, Schäffeler E, Winter S, Schwab M, Gawaz M, Geisler T. Stimpfle F, et al. Among authors: karathanos a. Thromb Res. 2014 Jul;134(1):105-10. doi: 10.1016/j.thromres.2014.05.006. Epub 2014 May 10. Thromb Res. 2014. PMID: 24856643 Clinical Trial.
Platelet expression of transforming growth factor beta 1 is enhanced and associated with cardiovascular prognosis in patients with acute coronary syndrome.
Rath D, Chatterjee M, Müller I, Müller K, Böckmann C, Droppa M, Stimpfle F, Karathanos A, Borst O, Seizer P, Langer H, Schwab M, Gawaz M, Geisler T. Rath D, et al. Among authors: karathanos a. Atherosclerosis. 2014 Dec;237(2):754-9. doi: 10.1016/j.atherosclerosis.2014.10.021. Epub 2014 Oct 30. Atherosclerosis. 2014. PMID: 25463116
High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
Geisler T, Booth J, Tavlaki E, Karathanos A, Müller K, Droppa M, Gawaz M, Yanez-Lopez M, Davidson SJ, Stables RH, Banya W, Zaman A, Flather M, Dalby M. Geisler T, et al. Among authors: karathanos a. PLoS One. 2015 Aug 28;10(8):e0135037. doi: 10.1371/journal.pone.0135037. eCollection 2015. PLoS One. 2015. PMID: 26317618 Free PMC article. Clinical Trial.
Combination of high on-treatment platelet aggregation and low deaggregation better predicts long-term cardiovascular events in PCI patients under dual antiplatelet therapy.
Müller KA, Karathanos A, Tavlaki E, Stimpfle F, Meissner M, Bigalke B, Stellos K, Schwab M, Schaeffeler E, Müller II, Gawaz M, Geisler T. Müller KA, et al. Among authors: karathanos a. Platelets. 2014;25(6):439-46. doi: 10.3109/09537104.2013.829914. Epub 2013 Oct 8. Platelets. 2014. PMID: 24102318 Free article. Clinical Trial.
Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).
Droppa M, Tschernow D, Müller KA, Tavlaki E, Karathanos A, Stimpfle F, Schaeffeler E, Schwab M, Tolios A, Siller-Matula JM, Gawaz M, Geisler T. Droppa M, et al. Among authors: karathanos a. PLoS One. 2015 Mar 23;10(3):e0121620. doi: 10.1371/journal.pone.0121620. eCollection 2015. PLoS One. 2015. PMID: 25799149 Free PMC article.
32 results